Xeris Biopharma Holdings, Inc. XERS

Company Overview

Xeris Biopharma Holdings, Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for endocrine, neurology, and gastrointestinal diseases. The company operates primarily within the specialty pharmaceuticals and biotechnology industries, with a strategic emphasis on formulation science and drug-delivery technologies designed to improve the stability, usability, and administration of injectable therapies. Xeris generates revenue through commercialized products, licensing arrangements, and collaborations tied to its proprietary formulation platforms.

The company’s primary commercial products include Gvoke for severe hypoglycemia, Keveyis for primary periodic paralysis, and Recorlev for endogenous Cushing’s syndrome. A central differentiator is Xeris’ proprietary non-aqueous formulation technologies, including XeriSol and XeriJect, which are intended to enable room-temperature stable, ready-to-use injectable therapeutics. Founded in 2005 and headquartered in Chicago, Illinois, Xeris evolved from a drug-delivery platform company into a commercial-stage biopharmaceutical business through internal product development, regulatory approvals, and acquisitions, including the acquisition of Strongbridge Biopharma plc in 2021.